Stock Detail
ALNYLAM PHARMACEUTICALS INC
Biotechnology
ALNY @ Yahoo Finance | ALNY Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $6.74 | $6.92 | $-0.19 | -2.74% | 0.00 | $6.93 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $6.85 | $6.68 | 252,986 | 287.92M | 265,332.67 | -5.66 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 7.02 | 6.88 | 6.78 | 6.64 | 6.54 |
Stock Profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. The company is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases; and Systemic RNAi to treat a range of diseases, including oncology, metabolic, and autoimmune diseases. Its RNAi development programs are focused on an eye disease, known as age-related macular degeneration; and on a lung infection caused by a virus, known as human respiratory syncytial virus. The company also has multiple preclinical programs in Direct RNAi focused on a central nervous system disorder, known as Parkinson's disease; spinal cord injury; and a genetic disease, known as cystic fibrosis. In addition, Alnylam offers nontherapeutic license agreements to life science reagent and service providers. The company has strategic alliances and research collaborations with Merck & Co., Inc.; Medtronic, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; Mayo Foundation for Medical Education and Research; Novartis AG; and Mayo Clinic Jacksonville. Alnylam was founded by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore in 2002. The company is headquartered in Cambridge, Massachusetts.